Hemodynamic effects of levosimendan in acute myocardial infarction complicated by cardiogenic shock and high systemic vascular resistance

Acute Cardiac Care

Volumn 11, Issue 2, 2009, Pages 99-106

  Tsagalou, Eleftheria P ^a   Kanakakis, John ^a   Anastasiou Nana, Maria I ^a   Drakos, Stavros G ^a   Ntalianis, Argirios S ^a   Malliaras, Konstantinos ^a   Lazaris, Nikolaos ^a   Katsaros, Fotis ^a   Nanas, John N ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

acute myocardial infarction; cardiogenic shock; Levosimendan; peripheral vascular resistance

Indexed keywords

CATECHOLAMINE; LEVOSIMENDAN; HYDRAZONE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PYRIDAZINE DERIVATIVE; SIMENDAN;

ACUTE HEART INFARCTION; ADULT; AGED; CARDIOGENIC SHOCK; CLINICAL ARTICLE; CONFERENCE PAPER; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; FEMALE; HEART HEMODYNAMICS; HUMAN; MALE; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; VASCULAR RESISTANCE; ARTICLE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; FOLLOW UP; HEART INFARCTION; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEMODYNAMICS; HUMANS; HYDRAZONES; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PHOSPHODIESTERASE INHIBITORS; PYRIDAZINES; RETROSPECTIVE STUDIES; SHOCK, CARDIOGENIC; TIME FACTORS; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 70249123176     PISSN: 17482941     EISSN: 1748295X     Source Type: Journal    
DOI: 10.1080/17482940902807286     Document Type: Conference Paper

References (35)

1. Goldberg RJ, Samad NA, Yarzebski J, Gurwitz J, Bigelow C, Gore JM. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med. 1999;340: 1162-8. (Pubitemid 29177875)
2. Babaev A, Frederick PD, Pasta DJ, Every N, Sichrovsky T, Hochman JS; NRMI Investigators. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA. 2005;294:448-54. (Pubitemid 41124177)
3. Hochman JS, Boland J, Sleeper LA, PorwayM, Brinker J, Col J, et al. Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Results of an international registry. SHOCK Registry Investigators. Circulation. 1995;91:873-81.
4. Sonnenblick EH, Frishman WH, LeJemtel TH. Dobutamine: A new synthetic cardioactive sympathetic amine. N Engl J Med. 1979;300:17-22. (Pubitemid 9095978)
5. Colucci WS, Wright RF, Braunwald E. New positive inotropic agents in the treatment of congestive heart failure: Mechanisms of action and recent clinical developments. 2. N Engl J Med. 1986;314:349-58. (Pubitemid 16166262)
6. Felker GM, O'Connor CM. Inotropic therapy for heart failure: An evidence-based approach. Am Heart J. 2001;142:393-401. (Pubitemid 32801622)
7. Haikala H, Levijoki J, Linden IB. Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension. J Mol Cell Cardiol. 1995;27:2155-65.
8. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation. 2000;102:2222-7.
9. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000;36:1903-12.
10. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Steering Committee and Investigators of the levosimendan Infusion versus Dobutamine (LIDO) study: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial. Lancet. 2002;360:196-202. (Pubitemid 34804646)
11. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, et al; RUSSLAN study investigators: Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, doubleblind study (RUSSLAN). Eur Heart J. 2002;23:1422-32. (Pubitemid 36285574)
12. Sonntag S, Sundberg S, Lehtonen LA, Kleber FX. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol. 2004;43:2177-82. (Pubitemid 38757582)
13. Tsagalou EP, Nanas JN. Resuscitation from adrenalineresistant electro-mechanical dissociation facilitated by levosimendan in a young man with idiopathic dilated cardiomyopathy. Resuscitation. 2006;68:147-9. (Pubitemid 43053381)
14. Lilleberg J, Nieminen MS, Akkila J, Heikkila L, Kuitunen A, Lehtonen L, et al. Effects of a new calcium sensitizer, levosimendan, on hemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J. 1998;19:660-8. (Pubitemid 28224690)
15. Ozdem SS, Yalcin O, Meiselman HJ, Baskurt OK, Usta C. The role of potassium channels in relaxant effect of levosimendan in rat small mesenteric arteries. Cardiovasc Drugs Ther. 2006;20:123-7. (Pubitemid 43876095)
16. Usta C, Eksert B, Golbasi I, Bigat Z, Ozdem SS. The role of potassium channels in the vasodilatory effect of levosimendan in human internal thoracic arteries. Eur J Cardiothorac Surg. 2006;30:329-32. (Pubitemid 44051932)
17. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al. SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: The SURVIVE Randomized Trial. JAMA 2007;2;1883-91. (Pubitemid 46707842)
18. Lehmann A, Lang J, Boldt J, Isgro F, Kiessling AH. Levosimendan in patients with cardiogenic shock undergoing surgical revascularization: A case series. Med Sci Monit. 2004;10:T89-M93.
19. Garcia-Gonzalez MJ, Dominguez-Rodriguez A, Ferrer-Hita JJ. Utility of levosimendan, a new calcium sensitizing agent, in the treatment of cardiogenic shock due to myocardial stunning in patients with ST elevation myocardial infarction: A series of cases. J Clin Pharmacol. 2005;45:704-8. (Pubitemid 40696215)
20. Delle Karth G, Buberl A, Geppert A, Neunteufl T, Huelsmann M, Kopp C, et al. Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta Anaesthesiol Scand. 2003;47:1251-6. (Pubitemid 37452601)
21. Alhashemi JA. Treatment of cardiogenic shock with levosimendan in combination with beta-adrenergic antagonists. Br J Anaesth. 2005;95:648-50. (Pubitemid 41600027)
22. García-González MJ, Domínguez-Rodríguez A, Ferrer-Hita JJ, Abreu-Gonzalez P, Munoz MB. Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics. Eur J Heart Fail. 2006;8:723-8. (Pubitemid 44637270)
23. Karpman VL. The theoretical analysis of Fick's equation. On the centennial of the use of Fick's principle in physiology. Z Kardiol. 1975;64:801-8.
24. Cotter G, Williams SG, Vered Z, Tan LB. Role of cardiac power in heart failure. Curr Opin Cardiol. 2003;18:215-22. (Pubitemid 36960470)
25. Hochman JS. Cardiogenic shock complicating acute myocardial infarction: Expanding the paradigm. Circulation. 2003;107:2998-3002. (Pubitemid 36758968)
26. Kohsaka S, Menon V, Lange M, Dzavik V, Sleeper L, Hochman J. High incidence of suspected sepsis complicating cardiogenic shock following acute myocardial infarction. Circulation. 2001;104(Suppl II):II-483.
27. Lim N, Dubois MJ, De Backer D, Vincent JL. Do all nonsurvivors of cardiogenic shock die with a low cardiac index? Chest. 2003;124:1885-91. (Pubitemid 37433588)
28. Nanas JN, Papazoglou P, Tsagalou EP, Ntalianis A, Tsolakis E, Terrovitis JV, et al. Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone. Am J Cardiol. 2005;95:768-71. (Pubitemid 40332658)
29. Nanas J, Papazoglou P, Terrovitis J, Kanakakis J, Dalianis A, Tsolakis E, et al. Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone. Am J Cardiol. 2004;94:1329-32. (Pubitemid 39469964)
30. Depre C, Vanoverschelde JL, Goudemant JF, Mottet I, Hue L. Protection against ischemic injury by nonvasoactive concentrations of nitric oxide synthase inhibitors in the perfused rabbit heart. Circulation. 1995;92:1911-8.
31. Owlya R, Vollenweider L, Trueb L, Sartori C, Lepori M, Nicod P, et al. Cardiovascular and sympathetic effects of nitric oxide inhibition at rest and during static exercise in humans. Circulation. 1997;96:3897-903.
32. Cotter G, Kaluski E, Blatt A, Milovanov O, Moshkovitz Y, Zaidenstein R, et al. L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation. 2000;101:1358-61. (Pubitemid 30169854)
33. Alexander JH, Reynolds HR, Stebbins AL, Dzavik V, Harrington RA, Van de Werf F, et al. TRIUMPH Investigators: Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: The TRIUMPH randomized controlled trial. JAMA. 2007;297:1657-66. (Pubitemid 46631624)
34. Garatti A, Russo C, Lanfranconi M, Colombo T, Bruschi G, Trunfio S, et al. Mechanical circulatory support for cardiogenic shock complicating acute myocardial infarction: An experimental and clinical review. ASAIO J. 2007;53:278-87. (Pubitemid 46791532)
35. Russ MA, Prondzinsky R, Christoph A, Schlitt A, Buerke U, Söffker G, et al. Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. Crit Care Med. 2007; 35:2732-9. (Pubitemid 350175769)